RCM
CYTK icon

Riverhead Capital Management’s Cytokinetics CYTK Stock Holding History

Riverhead Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$131K Hold
11,500
– – ﹤0.01% 1257
2019
Q2 		$129K Hold
11,500
– – ﹤0.01% 1281
2019
Q1 		$93K Buy
11,500
+3,800
+49% +$27.9K ﹤0.01% 1340
2018
Q4 		$49K Buy
7,700
+2,800
+57% +$20.5K ﹤0.01% 1418
2018
Q3 		$48K Buy
4,900
+2,300
+88% +$18.5K ﹤0.01% 1494
2018
Q2 		$22K Buy
+2,600
New +$21.6K ﹤0.01% 1510

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Riverhead Capital Management's CYTK Position: Q3 2019 in Review

Riverhead Capital Management held its Cytokinetics (CYTK) position steady in Q3 2019 at 11,500 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

Riverhead Capital Management first reported a position in CYTK in Q2 2018 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

  • Riverhead Capital Management held 11,500 shares of Cytokinetics worth $131K as of Q3 2019.
  • Riverhead Capital Management left its Cytokinetics share count unchanged in Q3 2019.
  • Cytokinetics made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1257 holding.
  • Riverhead Capital Management first reported a position in Cytokinetics in Q2 2018 and has held it in 6 quarters since.
  • 148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.